All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

Core Viewpoint - All three leading proxy advisory firms, ISS, Glass Lewis, and Egan-Jones, have recommended that stockholders vote "FOR" Wendy L. Dixon, Ph.D. and Tamara A. Favorito, while advising to "WITHHOLD" votes for dissident nominees Travis Mickle and Arthur Regan, indicating a lack of compelling case for change from the dissident [1][2][4]. Proxy Advisory Recommendations - The Zevra Board of Directors expressed satisfaction with the unanimous endorsement from the proxy advisors, reinforcing their commitment to stockholder value creation under current leadership [2]. - Proxy advisors concluded that the dissident, Mangless, failed to provide sufficient arguments for electing his nominees, lacking a clear strategy to enhance stockholder value [2][5]. Shareholder Returns - Proxy advisors highlighted significant total shareholder returns under Zevra's current management, with ISS noting that the company has outperformed the broader biotech market during McFarlane's tenure as CEO [3][5]. - Egan-Jones emphasized that the past two years have yielded exceptional returns, surpassing both the total market and the S&P Biotech ETF [5]. Concerns About Dissident Nominees - ISS raised concerns about the potential disruption that electing the dissident nominees could cause, particularly highlighting the risks associated with having a former CEO on the board [5]. - Glass Lewis pointed out that Mangless did not present a meaningful alternative strategy for Zevra, lacking a clear plan to improve operational efficacy [5][13]. - Egan-Jones questioned the relevant expertise of Mangless' nominees, suggesting that their backgrounds do not offer meaningful value to Zevra's board [13].